<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435096</url>
  </required_header>
  <id_info>
    <org_study_id>2-55-52905-701</org_study_id>
    <nct_id>NCT01435096</nct_id>
  </id_info>
  <brief_title>BN80927 in Patients With Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the maximum tolerated dose and the recommended
      dose of BN80927 in patients with advanced malignant solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose determined by incidence of dose limiting toxicity.</measure>
    <time_frame>During cycle 1, up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose determined by incidence of dose limiting toxicity.</measure>
    <time_frame>During cycle 1, up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response assessment according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria.</measure>
    <time_frame>Baseline, week 3 of cycle 2, then on alternate cycles of treatment (maximum 10 cycles, up to 30 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>72 hours post-dose in treatment cycle 1 and 2</time_frame>
    <description>Cmax, Area Under Curve, Tmax, T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events.</measure>
    <time_frame>Monitored weekly at all treatment cycles and the end of study visit. Maximum 10 treatment cycles, up to 30 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <arm_group>
    <arm_group_label>BN80927</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BN80927</intervention_name>
    <description>Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.</description>
    <arm_group_label>BN80927</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All included patients:

          -  Gave their written (personally signed and dated) informed consent

          -  had histologically or cytologically documented malignant solid tumour

          -  had received no more than three prior chemotherapy regimens

          -  had failed the standard therapy or had no option of an active standard therapy

          -  had an estimated survival time of greater than 3 months (according to the
             investigator's assessment)

          -  had a World Health Organisation (WHO) performance status score ≤1

          -  were free from other serious concurrent disease

          -  had adequate bone marrow function

          -  had adequate liver function

          -  had adequate renal function

          -  who were female and of child-bearing potential must have had a negative result in a
             pre-study pregnancy test β-human-chorionic-gonadotrophin (β-HCG).

        Exclusion Criteria:

        No patient included:

          -  was pregnant or lactating

          -  was unable and/or unwilling to comply fully with the protocol and the study
             instructions;

          -  presented with any concomitant condition, which could compromise the objectives of the
             study

          -  had received an investigational drug within 30 days prior to study entry or was
             scheduled to require concurrent treatment with an experimental drug or treatment
             during the study

          -  had received chemotherapy or hormonotherapy within 4 weeks of study entry, or had
             received chemotherapy with nitrosoureas or mitomycin-C within 6 weeks of study entry

          -  had received any extensive palliative or curative radiotherapy (no more than 35% of
             their active bone marrow) within 2 weeks of study entry, or had not fully recovered
             from such treatment

          -  had previously received a bone marrow transplant (BMT) or peripheral blood progenitor
             cells (PBPC)

          -  had clinical evidence of major organ failure or brain metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>September 13, 2011</last_update_submitted>
  <last_update_submitted_qc>September 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

